ReviewMolecular biology reports2025
Neuroprotective mechanisms of microglia in ischemic stroke: a review focused on mitochondria.
Review in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- ACLY alleviates cerebral ischemia/reperfusion injury by reducing oxidative stress and enhancing mitochondrial function via histone acetylation.Cell death & disease · 2026Article
- Molecular mechanisms of mitochondrial function in neurodegenerative diseases.Molecular biology reports · 2025Article
- Exploring NMDAR pathways in ischemic stroke: implications for neurotoxic and neuroprotective mechanisms and therapeutic strategies.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Epigenetic Regulation in Ischemic Neuroprotection: The Dual Role of HDACs and HATs in Neuroinflammation and Recovery.Antioxidants (Basel, Switzerland) · 2025Review
- Targeting microglia polarization with Chinese herb-derived natural compounds for neuroprotection in ischemic stroke.Frontiers in cell and developmental biology · 2025Review
- Polyphenolic metabolites inFrontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Stroke encompasses a range of cerebrovascular disorders characterized by high morbidity, disability, and mortality, with ischemic stroke being the predominant type. This condition imposes significant socio-economic and healthcare burdens, and therapeutic options are currently limited. Microglia, the brain's resident immune cells, are rapidly activated following stroke-induced injury and play a pivotal role in the pathogenesis of neuroinflammation and ischemic tissues. Mitochondria participates in and influences the pathological processes of ischemic stroke, including oxidative stress, modulation of microglia phenotype, and axonal regenerative function, and is an essential and often overlooked target in the clinical management of stroke. This paper reviews recent advancements in research on microglia in ischemic stroke, specifically focusing on the contribution of the mitochondria, providing a reference for selecting therapeutic targets and guiding future research directions.
Indexed as
Identifiers
40167874What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.